High-dose rate brachytherapy in the treatment of low-risk prostate cancer
Objective: to conduct a retrospective evaluation of long-term oncological outcomes in patients with low-risk prostate cancer after high-dose rate brachytherapy in mono regimen with 8 years follow-up period. Material and methods: from 2008 to 2011 in the RSPC OMR them. N.N. Alexandrova was radically treated 59 low-risk prostate cancer patients, of which 58 continued to follow up after treatment. Stratification to the low-risk group was performed in accordance with the NCCN criteria. The follow-up period was 8 years. High-dose rate brachytherapy was performed using appropriate equipment. As the endpoints, the event-free, cancer specific, and overall patient’ survival was evaluated. Results: as a result of a retrospective analysis, 8-year event-free survival and cancer specific survival were 87,9 % and 96,6 %, respectively. The 8-year overall survival rate was 72,4 %. Conclusion: High-dose rate brachytherapy in mono regimen is characterized by good long-term oncological outcomes in patients with low-risk prostate cancer. Given the good tolerance and safety of high-dose rate brachytherapy, as well as the oncological results obtained, this method can be recommended as a radical treatment in patients with prostate cancer of the low-risk group.